FDA Issues Guidance on Biosimilar Labeling

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Labeling for Biosimilar and Interchangeable Biosimilar Products.” This draft guidance is intended to help applicants develop draft labeling for proposed biosimilar and interchangeable biosimilar products.

The recommendations for biosimilar and interchangeable biosimilar product labeling in the draft guidance pertain only to the prescribing information, except for certain recommendations pertaining to FDA-approved patient labeling ( e.g.,     Patient Information, Medication Guide, Instructions for Use).

The draft guidance provides an overview of FDA's recommendations for labeling for biosimilar and interchangeable biosimilar products. When finalized, this draft guidance will revise and replace the guidance for industry entitled “Labeling for Biosimilar Products.”

Source: Food and Drug Administration